Pfizer (PFE) Trims FY12 adj.-EPS Outlook on AstraZeneca (AZN) NEXIUM Deal
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $28.30 +1.84%
Financial Fact:
Research and development expenses: 1.88B
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development expenses: 1.88B
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) is updating its previous 2012 Adjusted R&D Expense guidance range from $6.5 - $7.0 billion to $6.75 - $7.25 billion and its previous 2012 Adjusted Diluted EPS guidance range from $2.14 - $2.24 to $2.12 - $2.22 and its previous 2012 Reported Diluted EPS guidance range from $1.23 - $1.38 to $1.21 - $1.36, while maintaining the other elements of its 2012 financial guidance.
The Street sees EPS of $2.22 for FY12.
The adjustments come following the OTC Nexium license acquisition deal with AstraZeneca (NYSE: AZN).
The Street sees EPS of $2.22 for FY12.
The adjustments come following the OTC Nexium license acquisition deal with AstraZeneca (NYSE: AZN).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
- Ocean Power Technologies revises fiscal 2026 results after audit
- TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
